Organoid-based model systems are increasingly being used to supplement or replace traditional models in preclinical drug testing. Organoids recapitulate the cellular complement of the modeled tissue and thus enable the detection of effects that may be missed in other models such as cell lines, which may not have all cell types of a specific tissue, or animal models, which may have limited relevance to human physiology. As such, many therapeutic development programs are now incorporating organoids as part of their preclinical discovery programs.